Viagra News and Research

RSS
Sildenafil citrate, sold as Viagra, Revatio and under various other trade names, is a drug used to treat erectile dysfunction and pulmonary arterial hypertension (PAH). It was developed and is being marketed by the pharmaceutical company Pfizer. It acts by inhibiting cGMP specific phosphodiesterase type 5, an enzyme that regulates blood flow in the penis. Since becoming available in 1998, sildenafil has been the prime treatment for erectile dysfunction; its primary competitors on the market are tadalafil (Cialis) and vardenafil (Levitra). It is frequently called the 'blue pill'.
Scientists develop new NO delivery system to fortify effects of Viagra in the body

Scientists develop new NO delivery system to fortify effects of Viagra in the body

Many herbal medicines banned under EU directives

Many herbal medicines banned under EU directives

Panax ginseng, saffron and yohimbine can boost human sexual function

Panax ginseng, saffron and yohimbine can boost human sexual function

New insight into Duchenne muscular dystrophy

New insight into Duchenne muscular dystrophy

A Medicare mistake: Paying for Viagra

A Medicare mistake: Paying for Viagra

First Edition: March 15, 2011

First Edition: March 15, 2011

'Cross-talk' between two major biological pathways may hold a clue for chronic pain treatment

'Cross-talk' between two major biological pathways may hold a clue for chronic pain treatment

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

LibiGel may be the first FDA approved product to treat HSDD in menopausal women

Man Up Now capsules can dangerously lower blood pressure

Man Up Now capsules can dangerously lower blood pressure

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

Political Ads, rhetoric on health law heating up races in Alaska, Nevada, Pennsylvania

Political Ads, rhetoric on health law heating up races in Alaska, Nevada, Pennsylvania

More support needed for erectile dysfunction says sexologist

More support needed for erectile dysfunction says sexologist

Prescription opioids can be gate way to illicit drug addiction: Study

Prescription opioids can be gate way to illicit drug addiction: Study

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Erectile dysfunction drug user over 40 more likely to have sexually transmitted diseases

Erectile dysfunction drug user over 40 more likely to have sexually transmitted diseases

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Magic Power Coffee can dangerously lower blood pressure, warns FDA

Magic Power Coffee can dangerously lower blood pressure, warns FDA

Regulators miss deadline on medical loss ratios: Other implementation developments continue to emerge

Regulators miss deadline on medical loss ratios: Other implementation developments continue to emerge

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

Study: PDE5 inhibitors may increase permeability of blood brain barrier to Herceptin

Today's Opinions and Editorials: The end of insurance rescissions, lessons from the health care rollout and the deficit panel's tough decisions

Today's Opinions and Editorials: The end of insurance rescissions, lessons from the health care rollout and the deficit panel's tough decisions

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.